Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

Mirtazapine is more likely to cause sedation at lower doses (e.g. 15mg) than at higher doses (e.g. 45mg).

The appropriate course of action is to increase the mirtazapine dose to 30mg at night. If there has been no improvement in symptoms after four weeks, it is reasonable to increase the dose to the usual minimum effective dose. It is important to note that sedation typically decreases with higher doses of mirtazapine due to increased noradrenergic activity.

If the patient does not respond to or cannot tolerate an increase in mirtazapine, switching to an alternative medication such as fluoxetine or venlafaxine may be considered. However, it is advisable to try the usual minimum effective dose of mirtazapine before deciding to switch medications.

Amitriptyline and other TCAs are no longer commonly used in the treatment of depression due to the risk of overdose.

In cases of severe depression, depression that does not respond to primary care management, or suspected bipolar disorder, it is recommended to seek a secondary care opinion.

Mirtazapine: An Effective Antidepressant with Fewer Side Effects

Mirtazapine is an antidepressant medication that functions by blocking alpha2-adrenergic receptors, which leads to an increase in the release of neurotransmitters. Compared to other antidepressants, mirtazapine has fewer side effects and interactions, making it a suitable option for older individuals who may be more susceptible to adverse effects or are taking other medications.

Mirtazapine has two side effects that can be beneficial for older individuals who are experiencing insomnia and poor appetite. These side effects include sedation and an increased appetite. As a result, mirtazapine is typically taken in the evening to help with sleep and to stimulate appetite.

Overall, mirtazapine is an effective antidepressant that is well-tolerated by many individuals. Its unique side effects make it a valuable option for older individuals who may have difficulty sleeping or eating.

Understanding Phobias and Dissociative Disorders

Phobias and dissociative disorders are two types of mental health conditions that can significantly impact a person’s daily life. Phobias are intense and irrational fears of specific objects or situations, while dissociative disorders involve a disconnection from reality as a coping mechanism.

Agoraphobia is a common and severe phobia that affects mostly women and involves a fear of open spaces and crowded places. Social phobia, on the other hand, is a fear of being scrutinized in public and tends to start in adolescence. Acrophobia is a specific phobia that involves a fear of heights.

Treatment for phobias often involves psychological interventions such as cognitive-behavioral therapy. Dissociative disorders, on the other hand, typically require more intensive therapy to address the underlying trauma that led to the dissociation.

It’s important to seek professional help if you or someone you know is struggling with a phobia or dissociative disorder. With the right treatment and support, it is possible to manage these conditions and improve overall quality of life.

To decrease the risk of relapse, it is recommended to continue antidepressant treatment for at least 6 months after remission of symptoms. Therefore, the correct response is to continue fluoxetine for at least 6 months at the same dose. It should be noted that in elderly patients, treatment should be continued for 12 months, and in those with a history of recurrent depression, treatment should be continued for 2 years. Stopping fluoxetine or tapering the dose over 2 weeks is not appropriate, as treatment should be continued for at least 6 months before considering stopping or tapering. When fluoxetine is stopped, it is recommended to taper the dose over 6-12 weeks to minimize the risk of withdrawal symptoms.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Management of Conduct Disorder: Interventions and Referrals

Conduct disorder is a psychiatric condition characterized by persistent patterns of aggressive and antisocial behavior. The management of conduct disorder involves a combination of pharmacological and psychosocial interventions. Here are some of the key interventions and referrals for managing conduct disorder:

Cognitive Behavioral Therapy (CBT): CBT techniques are used as part of the psychosocial interventions for conduct disorder. These techniques are considered as part of the first-line management of conduct disorder.

Methylphenidate: Methylphenidate is a medication that is used in the treatment of ADHD, which is often a coexisting condition with conduct disorder. This medication should only be initiated and coordinated by a specialist in secondary care (such as CAMHS).

Antidepressant Medications: Antidepressant medications should not be the first line in the management of conduct disorder, particularly with no coexisting health conditions. If there were depressive symptoms, these medications could be considered but are generally avoided in this age group.

Psychosocial Interventions: Psychosocial interventions are important in the management of conduct disorder. These include child-focussed programmes, multimodal interventions and parent training programmes. These interventions would be considered first-line management for conduct disorder if there was not the co-existing complicating factor of ADHD.

Referral to Child and Adolescent Mental Health Services (CAMHS): Patients presenting with symptoms of conduct disorder with a significant complicating factor should be referred to CAMHS for specialist assessment. These factors include mental health problems, neurodevelopmental disorder, learning disability or difficulty, and substance misuse. However, if the patient has already been referred to CAMHS, re-referral would not be necessary.

Managing Conduct Disorder: Interventions and Referrals

Elderly individuals taking antipsychotics are at a higher risk of experiencing stroke and VTE.

Antipsychotics are a group of drugs used to treat schizophrenia, psychosis, mania, and agitation. They are divided into two categories: typical and atypical antipsychotics. The latter were developed to address the extrapyramidal side-effects associated with the first generation of typical antipsychotics. Typical antipsychotics work by blocking dopaminergic transmission in the mesolimbic pathways through dopamine D2 receptor antagonism. They are associated with extrapyramidal side-effects and hyperprolactinaemia, which are less common with atypical antipsychotics.

Extrapyramidal side-effects (EPSEs) are common with typical antipsychotics and include Parkinsonism, acute dystonia, sustained muscle contraction, akathisia, and tardive dyskinesia. The latter is a late onset of choreoathetoid movements that may be irreversible and occur in 40% of patients. The Medicines and Healthcare products Regulatory Agency has issued specific warnings when antipsychotics are used in elderly patients, including an increased risk of stroke and venous thromboembolism. Other side-effects include antimuscarinic effects, sedation, weight gain, raised prolactin, impaired glucose tolerance, neuroleptic malignant syndrome, reduced seizure threshold, and prolonged QT interval.

If a person dies while under the mental health act, regardless of the cause of death, it is mandatory to report their death to the coroner. In this case, as the individual was detained under the mental health act at the time of their death, it is the responsibility of the doctors in the hospital where they passed away to issue the MCCD after discussing with the coroner. It would be inappropriate to ask the GP who performed their surgery over a year ago to issue the MCCD as they may not have seen the individual within 14 days prior to their death. Additionally, the doctors at the psychiatric hospital may have seen the individual within the 14 days prior, but it is still the responsibility of the hospital doctors who were caring for them at the time of their death to issue the MCCD.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

Completed suicide can be prevented by certain protective factors such as having social support, religious beliefs, having children at home, and regretting a previous attempt. It is important to note that the duration of mental illness is not a determining factor, but having a mental illness, especially depression, increases the risk. Alcohol misuse is also a risk factor, but in this scenario, the fact that the person does not drink much alcohol is not particularly protective. The individual in the scenario lacks social support and is not religious, making those options incorrect. However, having children present at home is a protective factor.

Suicide Risk Factors and Protective Factors

Suicide risk assessment is a common practice in psychiatric care, with patients being stratified into high, medium, or low risk categories. However, there is a lack of evidence on the positive predictive value of individual risk factors. A review in the BMJ concluded that such assessments may not be useful in guiding decision-making, as 50% of suicides occur in patients deemed low risk. Nevertheless, certain factors have been associated with an increased risk of suicide, including male sex, history of deliberate self-harm, alcohol or drug misuse, mental illness, depression, schizophrenia, chronic disease, advancing age, unemployment or social isolation, and being unmarried, divorced, or widowed.

If a patient has attempted suicide, there are additional risk factors to consider, such as efforts to avoid discovery, planning, leaving a written note, final acts such as sorting out finances, and using a violent method. On the other hand, there are protective factors that can reduce the risk of suicide, such as family support, having children at home, and religious belief. It is important to consider both risk and protective factors when assessing suicide risk and developing a treatment plan.

Differentiating Seasonal Affective Disorder from Other Depressive Disorders

Seasonal affective disorder (SAD) is a type of depression that occurs in a regular temporal pattern, typically beginning in autumn or winter and ending in spring or summer. Unlike classic major depression, SAD is characterized by symptoms of hyperphagia, hypersomnia, and weight gain. The cause of SAD is believed to be a malfunction of the light-sensitive hormone melatonin during winter. Treatment involves phototherapy, which exposes individuals to bright light for several hours a day.

Reactive depression, on the other hand, is a subtype of major depression that occurs as a result of an external event, such as a relationship breakdown or bereavement. There is no indication of a stressful life event in the presented vignette.

Bipolar affective disorder is characterized by distinct episodes of depression and mania, which is not evident in the vignette. Dysthymia is a persistent depression of mood that does not fully meet the criteria for a diagnosis of major depression and does not have a definite seasonal variation like SAD.

Finally, double depression occurs when one or more episodes of major depression occur on a background of dysthymia. It is important to differentiate SAD from other depressive disorders to provide appropriate treatment and management.

Differentiating Social Phobia from Other Anxiety Disorders

Social phobia, also known as social anxiety disorder, is a type of anxiety disorder characterized by intense fear and anxiety in social situations, particularly when being scrutinized. It typically starts in adolescence and affects both men and women equally. Some individuals may have a specific fear of certain situations, while others may experience anxiety in most social situations outside of close family and friends. Low self-esteem is often associated with social phobia, and avoidance of feared situations is common. Treatment typically involves psychological interventions such as cognitive-behavioral therapy.

It is important to differentiate social phobia from other anxiety disorders. Panic disorder is characterized by recurrent episodes of severe anxiety that occur unpredictably and without an objective danger. Agoraphobia involves a fear of situations where escape to a safe place is difficult or impossible. Generalized anxiety disorder is characterized by non-specific and persistent anxiety, often accompanied by autonomic and motor overactivity. Depression may also be associated with anxiety, but typically involves early morning waking rather than difficulty falling asleep.

By understanding the specific features of social phobia and how it differs from other anxiety disorders, healthcare professionals can provide appropriate diagnosis and treatment for their patients.